Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Multiple Myeloma — Faculty Presentation 2: Other Novel Strategies with Potential to Improve Outcomes in MM — Dr Landgren. CME information and select publications
Myeloma Crowd Radio: Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Ctr
Myeloma Crowd Radio
For the last 50 years, myeloma studies have relied on myeloma progression measurements like complete response (CR) or progression free survival (PFS) to tell whether new treatmets are working (or not). Myeloma patients are now living longer because of new treatment advances, which is a huge blessing. But it is also a challenge for research. If the average patient is living 8-10 years, how can studies be performed and show results in the 2-3 year range so that the new drugs can be approved quickly? Minimal residual disease testing can detect very low levels of disease and being MRD-negative is linked to patients living longer. Researchers would like to use MRD testing as a study measurement. Learn about the different types of MRD tests, how to have one done and why researchers want to use this test as an end-point in studies. Dr. Ola Landgren of the Memorial Sloan Kettering Cancer Center is a pioneer in the MRD space and joins us for this important show.Thanks to our episode sponsor, Takeda Oncology
Myeloma Crowd Radio: Dr. Ola Landgren, MD, PhD, Memorial Sloan Kettering
Myeloma Crowd Radio
New developments for multiple myeloma are happening at an ever increasing pace. Dr. Ola Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center and heavily involved in the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Working Group meeting as well as an ASH preview (for the upcoming December conference). He will also share up and coming clinical trials at Memorial Sloan Kettering Cancer Center to incorporate these new treatments into clinical practice. Learn what new drugs will be available and how they can be used in the myeloma clinic.
This week on mPatient Myeloma Radio, listen to Dr. Landgren as we discuss his research in new therapies for myeloma in its precursor states (MGUS and smoldering), molecular profiling of myeloma and why it is important in predicting progression, and his related research with myeloma and the immune system.